search
Back to results

Bacterial Air Contamination

Primary Purpose

Infection Control

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Intervention
Control
Sponsored by
Camilla Wistrand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infection Control focused on measuring Infection control

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Consecutive patients (n=70) undergoing cardiac surgery at the Department of Cardiothoracic and Vascular Surgery at Örebro University Hospital (ÖUH), Region Örebro County will be identified. Inclusion criteria: patients undergoing cardiac surgery by median sternotomy; coronary artery bypass grafting (CABG), aneurysm, valve replacement or combination surgery.

Exclusion Criteria:

  • Patients where partial thoracotomy or endovascular procedures are performed. Patients with infection and procedures as infective endocarditis. No research nurse available.

Sites / Locations

  • University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention

Control

Arm Description

In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention).

The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons).

Outcomes

Primary Outcome Measures

Colony forming units
Bacterial growth

Secondary Outcome Measures

Full Information

First Posted
October 24, 2022
Last Updated
October 24, 2022
Sponsor
Camilla Wistrand
search

1. Study Identification

Unique Protocol Identification Number
NCT05597072
Brief Title
Bacterial Air Contamination
Official Title
Infection Control - Time-dependant Bacterial Air Contamination in the Operating Room
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2022 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Camilla Wistrand

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Aim is to compare the effect of number of persons and time-dependant bacterial air contamination on sterile goods, using different preparation conditions and protective sterile covers. Research questions Is there a difference in bacterial air contamination during preparation of the sterile surgical goods with 2 persons (intervention) compared with 4-5 persons (control) in the OR? Is there a time-dependent difference in bacterial air contamination pending surgery for 1 hour (control) compared to approximately 12 hours (intervention) when the sterile goods are protected with sterile covers? Is there a time-dependent difference in bacterial air contamination pending surgery if sterile goods are protected or not, by sterile covers? Is there any differences in surgical site infections between the groups? What type of bacteria contain the air contamination? Is there antibiotic resistant bacterial air contamination?
Detailed Description
Intervention - In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention). The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons). Thereafter, the sterile goods will be protected with sterile covers (time pending surgery will be approximately one hour). For allocation, a computer-generated randomization list will be produced and an independent secretary will be arranging the printed notes showing the group assignment in ordered, sealed, non-transparent envelopes. To measure the time pending surgery tables will be arrange with blood agar plates to measure the bacterial air contamination. There will be two tables, one protected with sterile covers and one left without protective covers (in both intervention- and control group). Outcomes and materials - Primary outcome is bacterial growth isolated by aerobe and anaerobe blood agar plates (haematin agar medium 4.3% w/v [Colombia Blood Agar Base] supplemented with 6% w/v chocolatized defibrinated horse blood) and FAA plates (LAB 90 Fastidious Anaerobe Agar 4.6% w/v supplemented with 5% w/v defibrinated horse blood). Secondary outcome is surgical site infections with comparison of bacteria type. Data collection - A total of 1260 blood agar plates will be used to capture bacterial air contamination. To capture differences in bacterial air contamination during different preparation conditions of the sterile goods, six agar plates (three haematin and three FAA) will be set on a table as the preparation begins. When preparation is complete the agar plates will be collected, by closing the lid of the agar plates. To measure the time-dependant bacterial air contamination pending surgery new agar plates (three haematin and three FAA) which will be set on tables for both intervention- and control group and covered with sterile drapes. To measure the effectiveness of sterile coverage from bacterial air contamination agar plates will be left uncovered pending surgery in both intervention- and control group. When preparing the patient for surgery the covers will be removed and all the plates will be collected by closing the lids. Microbiology - The plates will be analysed at the Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, according to a specific study protocol. The haematin plates will be incubated at 36°C under aerobic conditions while the FAA plates will be incubated under anaerobic conditions (10% H2, 10% CO2, 80% N2) at 37°C. After 24 and 48 h of aerobic incubation and five days of anaerobic incubation, bacterial growth will be determined quantitatively by counting colony-forming units per plate. The isolates will be identified by routine diagnostic procedures and determined to species level via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Microflex LT and Biotyper 3.1, Bruker Daltonik, Bremen, Germany). Standard antibiotic susceptibility testing for staphylococci will be performed by the disc diffusion test for cefoxitin (30 mg), fusidic acid (10 mg), erythromycin (15 mg), clindamycin (2 mg), trimethoprim/sulfamethoxazole (25 mg), gentamicin (10 mg), norfloxacin (10 mg), ciprofloxacin (5 mg), and rifampin (5 mg) (all antibiotic discs from Oxoid, Basingstoke, UK) with a 0.5 McFarland bacterial suspension in 0.85% NaCl on Mueller-Hinton II agar 3.8% w/v plates (BD Diagnostic Systems, Sparks, MD, USA). After 16-20 h of incubation at 35°C, the zone diameters will be measured and each isolate will be evaluated according to European Committee on Antimicrobial Susceptibility Testing breakpoints (http://www.eucast.org). Isolates resistant to at least three of the antibiotic groups tested will be considered multidrug resistant. The susceptibility of Cutibacterium acnes to benzylpenicillin and clindamycin will be investigated using a gradient test. Minimum inhibitory concentrations will be determined by Etest (bioMe´rieux, Marcy l'Etoile, France) on FAA plates (LAB M) with 0.5 McFarland suspensions of bacteria in NaCl and incubation at 36°C in an anaerobic atmosphere for 24 h. For metronidazole, a disc (Oxoid) will be used. Bacterial genomic sequencing may be analysed in order to understand if the bacteria derives from the persons within the OR or the hospital environment. All data regarding postoperative infections will be retrieved from a local register Carath, Department of Cardiothoracic and Vascular surgery. A case report form (CRF) will be used to collect data regarding patient characteristics, OR settings (e.g. temperature, air humidity, number of persons, number of door openings) and surgical data (e.g. type of surgery, time for surgery).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection Control
Keywords
Infection control

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
Participant
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention).
Arm Title
Control
Arm Type
Active Comparator
Arm Description
The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons).
Intervention Type
Behavioral
Intervention Name(s)
Intervention
Intervention Description
Less people within the OR but longer waiting time.
Intervention Type
Behavioral
Intervention Name(s)
Control
Intervention Description
More people in the OR but shorter waiting time
Primary Outcome Measure Information:
Title
Colony forming units
Description
Bacterial growth
Time Frame
from one to 15 hours

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Consecutive patients (n=70) undergoing cardiac surgery at the Department of Cardiothoracic and Vascular Surgery at Örebro University Hospital (ÖUH), Region Örebro County will be identified. Inclusion criteria: patients undergoing cardiac surgery by median sternotomy; coronary artery bypass grafting (CABG), aneurysm, valve replacement or combination surgery. Exclusion Criteria: Patients where partial thoracotomy or endovascular procedures are performed. Patients with infection and procedures as infective endocarditis. No research nurse available.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Camilla Wistrand, PhD
Phone
+46707686938
Email
camilla.wistrand@regionorebrolan.se
First Name & Middle Initial & Last Name or Official Title & Degree
Ann-Sofie Sundqvist, PhD
Email
ann-sofie.sundqvist@regionorebrolan.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Camilla Wistrand, PhD
Organizational Affiliation
Örebro University, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Örebro
ZIP/Postal Code
70185
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Camilla Wistrand, PhD
Phone
+46707686938
Email
camilla.wistrand@regionorebrolan.se
First Name & Middle Initial & Last Name & Degree
Ann-Sofie Sundqvist
Email
ann-sofie.sundqvist@regionorebrolan.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bacterial Air Contamination

We'll reach out to this number within 24 hrs